Phospho-eNOS (Thr495) Polyclonal Antibody, PE Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-3731R-PE |
| Product Name | Phospho-eNOS (Thr495) Polyclonal Antibody, PE Conjugated |
| Applications |
WB
FCM
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human, Mouse |
| Predicted Reactivity | Rat, Dog, Cow, Sheep, Pig, Rabbit, GuineaPig |
| Specifications | |
| Conjugation | PE |
| Host | Rabbit |
| Source | KLH conjugated synthetic phosphopeptide derived from human eNOS around the phosphorylation site of Thr495 |
| Modification Site | Thr495 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 4846 |
| Swiss Prot | P29474 |
| Subcellular location | Cytoplasm, Cell membrane |
| Synonyms | eNOS; ECNOS; Nitric oxide synthase, endothelial; Constitutive NOS; cNOS; EC-NOS; Endothelial NOS; NOS type III; NOSIII; NOS3 |
| Background | Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets. Isoform eNOS13C: Lacks eNOS activity, dominant-negative form that may down-regulate eNOS activity by forming heterodimers with isoform 1. |
| Application Dilution | |
| WB | 1:300-5000 |
| FCM | 1:20-100 |
| IF(IHC-P) | |
| IF(IHC-F) | |
| IF(ICC) | |